Eqrx Inc - EQRX STOCK NEWS

EQRx has received acceptance for a marketing authorization application (MAA) from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for aumolertinib, a third-generation EGFR-tyrosine kinase inhibitor. This application marks EQRx’s first submission to a regulatory agency and is supported by data from the Phase 3 AENEAS trial for treating EGFR-mutated non-small cell lung cancer (NSCLC). If approved, aumolertinib could become a key treatment option for the significant patient population in the U.K.

EQRx, a pharmaceutical company focused on delivering innovative medicines at lower prices, announced participation in two investor conferences in June 2022. The Jefferies Global Healthcare Conference will feature a fireside chat on June 9, 2022, at 11:30 a.m. PT, while the Goldman Sachs 43rd Annual Global Healthcare Conference will host a chat on June 14, 2022, at 4:00 p.m. PT. Live webcasts of these discussions will be accessible on EQRx's website. The company aims to revolutionize the pharmaceutical sector with cost-effective and efficient drug development.

EQRx announced promising results from clinical trials for sugemalimab and aumolertinib targeting lung cancer. The Phase 3 trial showed sugemalimab, combined with chemotherapy, improved median overall survival by 8.5 months in Stage IV non-small cell lung cancer (NSCLC). In Phase 2, sugemalimab led to a 46.2% response rate in relapsed extranodal natural killer/T-cell lymphoma. Aumolertinib reduced CNS disease progression risk by 68% in advanced EGFR-mutated NSCLC. Data will be presented at the 2022 ASCO Annual Meeting to support regulatory submissions.

EQRx reported strong financial results for Q1 2022, with cash and equivalents totaling $1.6 billion, sufficient to fund operations into 2025. The company is advancing its lead oncology programs, aumolertinib and sugemalimab, with data presentations scheduled for the ASCO Annual Meeting. Regulatory submissions for both drugs are expected in 2H 2022 outside the U.S., while ongoing discussions with the FDA aim to clarify the U.S. regulatory path. Operating expenses increased significantly compared to Q1 2021, totaling $85.7 million.

EQRx, a pharmaceutical company focused on delivering innovative medicines at lower prices, will host a conference call on May 13, 2022, at 8:00 a.m. ET to discuss its first quarter 2022 financial results and provide a business update. Interested parties can join the live webcast on the investor section of the company's website or by dialing in. EQRx aims to revolutionize drug affordability through strategic partnerships and cutting-edge technology.

EQRx, a pharmaceutical company focused on affordable medicine, announced key data presentations for its oncology programs at the upcoming ASCO Annual Meeting (June 3-7, 2022). This includes the Phase 3 GEMSTONE-302 study on sugemalimab for untreated Stage IV non-small cell lung cancer (NSCLC) and the Phase 2 GEMSTONE-201 study concerning relapsed extranodal NK/T-cell lymphoma. Additionally, data on aumolertinib's effectiveness in treating CNS metastases in EGFR-mutated NSCLC will be presented. These presentations aim to showcase EQRx's commitment to developing innovative, cost-effective treatments.

EQRx announced its financial results for 2021, reporting a cash position of $1.7 billion as of December 31, 2021, with a projected runway into 2025. The company aims to submit regulatory applications for its oncology drugs, aumolertinib and sugemalimab, outside the U.S. in 2H 2022. Positive Phase 3 data were highlighted, showing significant clinical progress in treating non-small cell lung cancer. EQRx also seeks partnerships covering 350 million lives by year-end and reported decreased research and development expenses for the year.

EQRx, a pharmaceutical company focused on providing innovative medicines at lower prices, announced a conference call on March 23, 2022, at 8:00 a.m. ET. The call will cover the financial results for Q4 and the full year 2021, along with a business update. Interested parties can join via a live webcast or by calling the provided numbers. EQRx, launched in January 2020, aims to efficiently develop medicines with strategic partnerships in the healthcare system, targeting high-cost drug categories.

EQRx, a pharmaceutical company focused on providing innovative medicines at lower prices, will participate in a fireside chat at Cowen’s 42nd Annual Health Care Conference on March 9, 2022, at 12:50 p.m. ET. Investors and interested parties can access a live and archived webcast of the chat via EQRx’s website in the Events & Presentations section. Launched in January 2020, EQRx collaborates with stakeholders to deliver cost-effective, patent-protected medicines, catering to high-cost drug categories.